Table 1 Patient Demographics and MDS Disease Characteristics (N = 54)
Age (years) | |
|---|---|
Median | 70 |
Range | 22–90 |
Age By Decade | n (%) |
< 60 | 8 (15) |
61 – < 70 | 19 (35) |
70 – < 80 | 18 (33) |
≥ 80 | 9 (17) |
Gender | |
Male | 35 (65) |
Female | 19 (35) |
Baseline Performance Status (ECOG) | |
0 | 18 (33) |
1 | 30 (56) |
2 | 4 (7) |
Unknown | 2 (4) |
Race | |
Caucasian | 48 (88) |
Hispanic | 3 (6) |
Asian | 1 (2) |
Black | 1 (2) |
Other | 1 (2) |
FAB Classification | |
RA | 30 (56) |
RARS | 9 (17) |
RAEB | 9 (17) |
RAEB-t | 3 (6) |
CMML | 1 (2) |
Unknown | 2 (4) |
Baseline Karyotype | |
Abnormal | 27 (50) |
Normal | 27 (50) |
IPSS Score | |
Low | 39 (72) |
Intermediate | 1 (2) |
High | 12 (22) |
Unknown | 2 (4) |
Prior Therapy | |
Blood Product Support | 41 (76) |
r-EPO | 29 (54) |
G-CSF | 8 (15) |
Steroids | 6 (11) |
Thalidomide/Lenalidomide | 10 (18) |
Other Chemotherapy | 8 (15) |
5-Azacitadine | 7 (13) |
Vitamins | 3 (6) |
GM-CSF | 1 (2) |
Baseline Hematologic Values | Median (Range) |
ANC | 1.4 (0.0–27.3) |
HCT | 27.0 (19.3–37.8) |
Hgb | 9.1 (6.7–12.6) |
Platelet Count | 70.0 (9.0–890) |